Option chain shows key data for Lonza Group's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Lonza Group.

Lonza Group (OTC:LZAGF) Stock, Option Chain

Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.

Roche

Biotech

News

Health Care

General

LZAGF

LZAGY

RHHBY

Lonza expands biologics manufacturing capacity with acquisition of Genentech facility in Vacaville, CA. $1.2 billion deal includes employee retention and facility upgrades. Transaction expected to boost sales growth. Closing anticipated by H2 2024.

Swiss Healthcare Manufacturing Firm Lonza Bolsters Biologics Manufacturing Capacity With Roche&#39;s US Facility Acquisition For $1.2B

GLPG

Galapagos Bets €225M On CellPoint Marking Its Entry Into CAR-T Field

Contracts

MRNA


	Moderna Inc (NASDAQ: MRNA) is gearing up to halve the dose of its COVID-19 vaccine so that it can also be used to combat variants and inoculate children.


Moderna, Lonza Team Up To Produce New Drug Substance for COVID-19 Vaccine Doses

Lonza Group Ltd

Madison International Stock Fund Q1 2024 Investment Strategy Letter

Artisan International Fund Q1 2024 Commentary

Lonza Group AG (LZAGY) Q1 2024 Earnings Call Transcript

Medpace: Clear Winner If China Blockade Succeeds

Artisan International Fund Q2 2024 Commentary

Lonza Group AG 2024 Q2 - Results - Earnings Call Presentation

Lonza Group AG (LZAGY) Q2 2024 Earnings Call Transcript

Innospec Navigating Turbulent End-Markets And Specialty Chemical De-Rating Relatively Well

Thermo Fisher plant making Astra/ Sanofi RSV drug reportedly breached FDA rules

Baron Emerging Markets Fund Q3 2024 Shareholder Letter

AAGIY

AAIGF

AMZN

APAM

ARGNF

ARGX

ASML

ASMLF

ASND

BABA

BABAF

BAESF

BAESY

BAIDF

BAMXF

BCAP

BIDU

BMWYY

BROE

BYMOF

CABGY

CABJF

CATL

CIADF

CIADY

CLZNF

CLZNY

CTLT

DGEAF

DSFIY

DSKYF

DSMFF

DSNKY

EADSF

EADSY

EVKIF

EVKIY

FUJIF

FUJIY

HEINY

HINKF

HXSCF

ICLR

INPOF

INPOY

IOSP

KIGRY

KNNGF

KYCCF

LZRFY

MBGAF

MBGYY

MEDP

MIELF

MIELY

MITEF

MITEY

MLSPF

MPNGF

MPNGY

MRAAF

MRAAY

MSCI

MTSFF

MTSFY

NONOF

NSRGF

NSRGY

NVDA

PDRDF

PRNDY

RHHBF

RHHVF

RSNHF

RYAAY

RYAOF

SAFRF

SAFRY

SNYNF

SONY

SSNLF

STLA

SVNDF

SVNDY

TCEHY

TCTZF

TMNSF

TMSNY

TOYOF

TSLA

TSMWF

UCBJF

UCBJY

WEGZY

WMMVF

WMMVY

WXIBF

WXXWY

WZZAF

WZZZY

Small Cap

Press Releases

NeuroSense Announces First Quarter 2024 Business Update

NRSN

Lonza Group

Comments

Lonza Group

Lonza Group (LZAGF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga